Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Pending | |||
| TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Pending | |||
| Repatha | Evolocumab | Primary hyperlipidemia and mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Repatha | Evolocumab | Primary hyperlipidemia; mixed dyslipidemia | List with clinical criteria and/or conditions | Complete | ||
| Repatha | evolocumab | Primary hyperlipidemia | Active | |||
| Evkeeza | evinacumab | Homozygous familial hypercholesterolemia (HoFH) | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | everolimus | Tuberous Sclerosis Complex (TSC) | Active | |||
| Afinitor | Everolimus | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
| Afinitor | Everolimus | Advanced Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Afinitor | Everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) | Do not list | Complete |
Last Updated : May 18, 2024